華勝天成(600410.SH):子公司擬1000萬元參與認購私募基金份額
格隆匯8月7日丨華勝天成(600410.SH)公佈,公司之全資子公司天津華勝擬與其他合夥人簽署《蘇州凱恩一號股權投資合夥企業(有限合夥)有限合夥協議》(稱“合夥協議”)等相關基金認購文件,共同出資參與認購私募股權投資基金“蘇州凱恩一號股權投資合夥企業(有限合夥)”,其中,天津華勝作為有限合夥人以自有資金人民幣1,000萬元參與認購基金份額。
基金擬募集的總規模為1億元人民幣(具體以合夥企業募集完成情況為準),投資方式以股權投資為主,主要投資於大數據、人工智能、智能製造等領域具有行業領先地位的企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.